A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

January 31, 2014

Study Completion Date

April 30, 2014

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Ustekinumab

subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28

Trial Locations (1)

9700RB

University Medical Centre Groningen, Groningen

All Listed Sponsors
collaborator

Janssen-Cilag B.V.

INDUSTRY

lead

University Medical Center Groningen

OTHER

NCT01704534 - A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter